A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology
Open Access
- 1 June 2011
- journal article
- research article
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. 6, 373-383
Abstract
Abstract: Antibiotics, along with oral corticosteroids, are standard treatments for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). The ultimate aims of treatment are to minimize the impact of the current exacerbation, and by ensuring complete resolution, reduce the risk of relapse. In the absence of superiority studies of antibiotics in AECOPD, evidence of the relative efficacy of different drugs is lacking, and so it is difficult for physicians to select the most effective antibiotic. This paper describes the protocol and rationale for MAESTRAL (moxifloxacin in AECBs [acute exacerbation of chronic bronchitis] trial; www.clinicaltrials.gov: NCT00656747), one of the first antibiotic comparator trials designed to show superiority of one antibiotic over another in AECOPD. It is a prospective, multinational, multicenter, randomized, double-blind controlled study of moxifloxacin (400 mg PO [per os] once daily for 5 days) vs amoxicillin/clavulanic acid (875/125 mg PO twice daily for 7 days) in outpatients with COPD and chronic bronchitis suffering from an exacerbation. MAESTRAL uses an innovative primary endpoint of clinical failure: the requirement for additional or alternate treatment for the exacerbation at 8 weeks after the end of antibiotic therapy, powered for superiority. Patients enrolled are those at high-risk of treatment failure, and all are experiencing an Anthonisen type I exacerbation. Patients are stratified according to oral corticosteroid use to control their effect across antibiotic treatment arms. Secondary endpoints include quality of life, symptom assessments and health care resource use.Keywords
This publication has 40 references indexed in Scilit:
- Susceptibility to Exacerbation in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2010
- Direct costs of chronic obstructive pulmonary disease among managed care patientsInternational Journal of Chronic Obstructive Pulmonary Disease, 2010
- Temporal Clustering of Exacerbations in Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Exacerbations worsen the quality of life of chronic obstructive pulmonary disease patients in primary healthcareInternational Journal Of Clinical Practice, 2008
- COPD exacerbations: defining their cause and preventionThe Lancet, 2007
- Inflammatory changes, recovery and recurrence at COPD exacerbationEuropean Respiratory Journal, 2006
- Chronic Obstructive Pulmonary Disease, Risk Factors, and Outcome Trials: Comparisons with Cardiovascular DiseaseProceedings of the American Thoracic Society, 2006
- Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitisThorax, 2006
- Clinical Significance of the Infection-FreeInterval in the Management of Acute Bacterial Exacerbations of Chronic BronchitisChest, 2005
- Antibiotics in the treatment of acute exacerbations of chronic bronchitisExpert Opinion on Investigational Drugs, 2002